



Medical Coverage Policy

Effective Date12/15/2024

Next Review Date12/15/2025

Coverage Policy Number..... 0552

Stem Cell Therapy for Orthopaedic Applications

Table of Contents

Overview	2
Coverage Policy	2
Health Equity Considerations.....	2
General Background.....	3
Medicare Coverage Determinations	13
Coding Information	13
References.....	14
Revision Details.....	19

Related Coverage Resources

[Autologous Platelet-Derived Growth Factors \(Platelet Rich Plasma \[PRP\]\)](#)
[Bone Graft Substitutes](#)
[Stem Cell Transplantation: Blood Cancers](#)
[Stem Cell Transplantation: Non-Cancer Disorders](#)
[Stem Cell Transplantation: Solid Tumors](#)

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment where appropriate and have discretion in making individual coverage determinations. Where coverage for care or services does not depend on specific circumstances, reimbursement will only be provided if a requested service(s) is submitted in accordance with the relevant criteria outlined in the applicable Coverage Policy, including covered diagnosis and/or procedure code(s). Reimbursement is not allowed for services when billed for conditions or diagnoses that are not covered under this Coverage Policy (see "Coding Information" below). When billing, providers

must use the most appropriate codes as of the effective date of the submission. Claims submitted for services that are not accompanied by covered code(s) under the applicable Coverage Policy will be denied as not covered. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Overview

This Coverage Policy addresses stem cell therapy to re-grow (also known as regenerate), damaged or missing cells and tissues in the muscles and skeleton utilizing mesenchymal stem cells (MSCs). MSCs are found in several types of tissues, including the bone marrow, and are important for making and repairing skeletal tissues, such as cartilage, bone and the fat found in bone. This type of stem cell therapy is known as regenerative therapy. Regenerative therapy is considered a field of medicine that is still under development.

For the intent of this Coverage Policy “stem cell therapy” refers to mesenchymal stem cells that are taken from bone marrow, fat tissue, amniotic membrane, and blood and membrane in the joints.

Stem cell transplantation using stem cells for treatment of blood cancer, non-cancer conditions and solid tumors are not in scope of this policy.

Please review Cigna Medical Coverage Policy 0118 Bone, Cartilage and Ligament Graft Substitutes for uses other than those discussed in this Coverage Policy.

Coverage Policy

Stem cell therapy as treatment of orthopaedic and/or musculoskeletal conditions, is considered not medically necessary for the following indications:

- regeneration and/or repair of musculoskeletal tissue (e.g., ligament, tendon, and/or meniscus repair, muscle sprain, tendonitis, epicondylitis)
- treatment of joint disease (e.g., articular cartilage repair, joint capsular injury)
- osteoarthritis (e.g., knee, hip, ankle, shoulder)
- fracture repair, including nonunion of long bone
- osteonecrosis repair

Health Equity Considerations

Health equity is the highest level of health for all people; health inequity is the avoidable difference in health status or distribution of health resources due to the social conditions in which people are born, grow, live, work, and age.

Social determinants of health are the conditions in the environment that affect a wide range of health, functioning, and quality of life outcomes and risks. Examples include safe housing, transportation, and neighborhoods; racism, discrimination and violence; education, job opportunities and income; access to nutritious foods and physical activity opportunities; access to clean air and water; and language and literacy skills.

General Background

Stem cells are cells that have the ability to differentiate into a number of various cell types and are being used more frequently in the treatment of orthopaedic and/or musculoskeletal conditions. There are various types of stem cells which include but are not limited to embryonic, mesenchymal, and hematopoietic. Embryonic stem cells are isolated from embryonic tissue, while both mesenchymal and hematopoietic are isolated using adult bone marrow. While some stem cells are restricted to a few lineages others may differentiate into a wide variety of cell types. Hematopoietic stem cell transplantation is the only well-established stem cell therapy in clinical practice (Gepstein and Skorecki, 2020).

According to the U.S. National Institute of Health (NIH), regenerative medicine “includes using stem cells and other technologies – such as engineered biomaterials and gene editing – to repair or replace damaged cells, tissues, or organs” (NIH, 2022). In general, cellular therapies are purported to produce a regenerative effect by promoting growth and differentiation of local cells. In addition, stem cells possess paracrine and immune-modulating effects through growth factor and cytokine release. Theoretically, stem cells inhibit the release of pro-inflammatory cytokines and promote the survival of existing cells and the repair of damaged tissue.

Within orthopaedics, mesenchymal stem cells are derived mainly from bone marrow, however other sources include adipose tissue (i.e., lipoaspirate), umbilical cord tissue, amniotic fluid, and other extra-articular sources. Mesenchymal stem cells (MSCs) are adult-derived, undifferentiated, multipotent cells that express a variety of different cell surface proteins and can differentiate into a variety of lineages, such as adipogenic (fat cells), osteogenic (bone cells), and chondrogenic (cartilage cells). Adult MSCs do not reach pluripotency, which is the ability to differentiate into all cell types derived from three germ layers (i.e., ectoderm, mesoderm, endoderm) of the developing embryo (e.g., embryonic stem cell). If MSCs are placed within normal healthy bone, cartilage, or adipose tissue, the stem cells differentiate into that particular tissue. In theory, this property applies to all mesenchymal tissues, including muscle, tendon, and fibrous tissues. MSCs demonstrate little to no ability however to differentiate into nonmesenchymal tissue (e.g., neural or hepatic cells) (Cook, Young, 2022).

MSCs are immunosuppressive and as such do not result in host rejection. One of the proposed advantages of autologous MSCs is the ability to isolate them, expand them in vitro and deliver them as autologous therapy. Nevertheless both autologous and allogenic MSCs are being used as therapy to treat various orthopaedic conditions. Although processing techniques vary, and the optimal number of MSCs to be transplanted/seeded has yet to be established, MSCs can be concentrated for direct injection, or they be cultured and incubated. Once cultured MSCs can be mixed with other materials such as gels or pastes, or they can be seeded onto scaffolds and used as a support matrix for implantation. Seeded scaffolds have been investigated as a tissue-engineering method within the musculoskeletal system for bone and cartilage repair. However, stem cells may undergo malignant transformation (Wang, et al., 2012) and there is some concern that autologous MSCs may induce tumors by changing the action of cancer cells and accelerating tumor growth, and further that allogeneic MSCs may accelerate infectious risk (Wang, et al., 2018).

The steps involved in processing MSCs include harvesting the cells from bone marrow or lipoaspirate, isolation of the cells, followed by proliferation in a culture medium (i.e., culture expanded). Following proliferation the MSCs are stored using cryopreservation. Other manufacturing procedures can be done that avoid cellular isolation and proliferation (i.e., nonexpanded cells) although the resulting number of stem cells within these products are unknown. Authors are also investigating autologous stromal vascular fraction (SVF) as adipose-

derived stem cells for regenerative treatment of osteoarthritis; SVF consists of nucleated stromal and vascular cells that are present in adipose tissue (progenitor and endothelial). SVF processing does not require cell expansion or culture (Garza, et al., 2020).

Treatment modalities for orthopaedic and/or musculoskeletal conditions proven safe and effective in the peer-reviewed medical literature include the use of pharmaceutical agents, weight loss, physical therapy and exercise, acupuncture, chiropractic care, and surgical repair when all other treatment options have failed. Stem cell therapy is an emerging technology that authors assert may be considered an alternative treatment modality and that may for some individuals avoid future surgical procedures (e.g., knee arthroplasty).

Please reference the Cigna Medical Coverage Policy 0118 Bone Graft Substitutes for information regarding demineralized bone matrix (DBM) and other products containing viable stem cells used to enhance healing of bone and 0507 Autologous Platelet-Derived Growth Factors (Platelet-Rich Plasma [PRP]) for use of PRP for orthopaedic indications.

Literature Review: Areas undergoing current investigation for the application of MSCs include but are not limited to regeneration and/or repair of musculoskeletal tissue, for example muscle, ligament, tendon, meniscus repair (Rinonapoli, et al., 2021; Centeno, et al., 2018a; Chew, et al., 2017; Lin, et al., 2017; Pas, et al., 2017b; Matsukura, et al., 2014; Centeno, et al., 2015; Vangsness, et al., 2014); treatment of joint disease, including, cartilage lesions, degenerative joint disease, and joint capsular injury (Ha, et al., 2019; Park, et al., 2018; Lee, Wang, 2017; Goldberg, et al., 2017; Filardo, et al., 2013; Ganjii, Hauzeur, 2009); osteoarthritis of the knee, hip, ankle, and shoulder (Wiggers, et al., 2021, Natali, et al., 2021; Garza, et al., 2020; Prodromos, et al., 2020; Simunec, et al., 2020; Lee, et al., 2019; Delanois, et al., 2019; Migliorini, et al., 2019; Emadedin, et al., 2018; Jevotovsky, et al., 2018; Centeno, et al., 2018b; Vannabouathong, et al., 2018; Pas, et al., 2017a; Cui, et al., 2016; Burke, et al., 2016; Vega, et al., 2015; Centeno, et al., 2014; Mobasheri, et al., 2014; Koh, et al., 2013; Pak, 2011); epicondylitis (Ahmad, et al., 2012); fracture (Yi, et al., 2022), including nonunion (Centeno, et al., 2011); and various spinal conditions such as spinal cord injury and intervertebral disc repair (Khan, et al., 2018).

The body of evidence in the published peer reviewed scientific literature evaluating MSCs for treatment of these conditions is mainly in the form of preliminary animal studies, case reports, case series, nonrandomized comparative trials, a number of systematic reviews/meta-analysis, and few randomized trials. The type/source of stem cell used and methods of extraction vary across studies, sample populations are small, reported outcomes are < two years in most studies, and injections include use of other components in some studies, such as hyaluronan or platelet rich plasma making it difficult to attribute the sole effect of MSCs as a treatment response. Regeneration and tissue remodeling has not been firmly established in well-designed, controlled studies and extraction and concentration methods, infusion procedures, indications for use are not standardized, and the optimal source of MSC including the quantity of cells to inject have not been firmly established. Additional RCTs evaluating long term outcomes are needed to firmly establish safety and efficacy of MSCs used for treatment of orthopaedic and /or musculoskeletal conditions. It is not yet proven that a clinical benefit outweighs potential harm that may be associated with MSC therapies.

Information available on the National Institutes of Health website regarding clinical trials indicates that several registered trials of MSCs for the treatment of osteoarthritis, tendon regeneration and other orthopaedic conditions are being conducted and few have been completed. The cells used within these trials include both expanded and nonexpanded MSCs for the treatment of a variety of orthopaedic and/or musculoskeletal conditions (NIH, 2024).

Some of the more commonly reported conditions under investigation include the following:

Meniscal Repair: The meniscus has poor intrinsic healing capacity. Use of stem cells for meniscal injuries has been performed in animals with few studies evaluating use in human meniscal injuries. A concern reported in the literature is the difference in mechanical properties in comparison with native meniscal tissue as well as differences in the extracellular matrix (Chew, et al., 2017). The presence of MSCs in synovial fluid following meniscal injury has been studied (Matsukura, et al., 2014). In comparison to normal knees MSCs were found to be present in higher numbers in synovial fluid with meniscus injury than normal knees. The authors postulated the presence of MSCs in synovial fluid contributed to spontaneous healing of the meniscus, and that additional studies are needed to determine if interventions that increase quantity of MSCs further promote meniscus healing.

MSCs as treatment of meniscal injury involves either intraarticular injection or local delivery to the site using a seeded scaffold (tissue engineering technique), however clinical trials are very limited in number, involve a limited number of subjects and have short follow-up. Authors of a 2021 systematic review evaluated stem cell applications for meniscal repair which included pre-clinical (n=13) and clinical studies (n=5; two case controls, one case report, one RCT and one case series (Rinonapoli, et al., 2021). They noted that based on the currently available evidence it is not possible to determine the best cell source or delivery method, although injection is the most studied and most promising. They further acknowledged that additional research and higher quality studies are needed to establish any clinical benefit.

A randomized controlled trial published by Vangsness, et al. (2014) involved 55 subjects who underwent partial medial meniscectomy (across seven facilities) and were randomized to one of three treatment groups: Group A, in which patients received an injection of 50×10^6 allogeneic mesenchymal stem cells; Group B, 150×10^6 allogeneic mesenchymal stem cells; and the control group, a sodium hyaluronate (hyaluronic acid/hyaluronan) vehicle control. Injection was given seven to 10 days following surgery, MSCs were cultured ex vivo and not human leukocyte antigen matched. Clinical outcomes were followed for two years and included safety, meniscal regeneration, and the overall condition of the knee joint. Knee pain was reported using VAS and Lysholm knee scales. Using VAS subjects who received MSC injections had a significant reduction in pain compared with the controls. MRI demonstrated a significant increase in meniscal volume, defined as a $>15\%$ threshold, in 24% (3 subjects) of subjects in Group A at two years indicating tissue regeneration according to the authors. A total of 427 adverse events were reported, 272 were mild, 126 were moderate, 28 were severe, and one was life threatening (heart attack one year post procedure). The most common adverse events were arthralgia, joint swelling, joint stiffness, injection-site joint pain, joint effusion, headache, and peripheral edema. Serious adverse events were deemed unlikely to be related to the treatment. The study is limited by small sample population, differences in MRI scans across facilities, and lack of control for osteoarthritis across groups as noted by the authors.

Osteonecrosis: Osteonecrosis is a progressive disease involving the death of bone tissue due to an impaired vascular supply. Osteonecrosis of the femoral head leads to femoral head collapse and need for subsequent hip arthroplasty. The implantation of stem cells into the necrotic lesion of the hip, resulting from osteonecrosis, has been studied in the medical literature as a method of preserving the femoral head. However, studies are in early stages and bone repair originating from the injected cell therapy has not been firmly established.

Li and colleagues published the results of a systematic review and meta analysis evaluating stem cell therapy combined with core decompression versus single biomechanical support as treatment of osteonecrosis of the femoral head. The analysis included 10 randomized controlled trials involving 498 subjects, 719 hips. A majority of the RCTs were not high quality, involved small

sample size (n=18-125), and had short term followup (2-3 yrs on average). Stem cell counts and source varied among studies. Clinical outcomes were assessed using Harris hip score, VAS, and adverse events. Publication bias was not able to be assessed and there was heterogeneity in outcome indicators. Based on the review the Harris hip score and VAS both differed when compared with the control group, favoring stem cell therapy for relief of pain and were statistically significant (MD=8.87, 95% CI, [P<0.00001]; MD=-14.07, 95% CI, [P<0.00001], respectively). There was no significant difference in adverse events among groups. According to the authors stem cell combined with core decompression was effective with few complications, however further high quality, large sample, multicenter long term RCTs are needed to establish safety and efficacy (Li, et al., 2021). Andronic et al. (2021) published the results of a systematic review comparing biologic augmentation combined with core decompression to core decompression alone as treatment of osteonecrosis of the femoral head. This review included 10 studies reporting on 560 hips (484 subjects), using bone marrow stem cells, platelet rich plasma or bone morphogenetic protein as the biological augmentation. It was noted only four studies reported improvement in all clinical scores in the augmentation group, seven studies observed a reduction in the rate of radiographic progression, and only 5 found reduced rates of conversion to total hip arthroplasty. The authors acknowledged the current evidence remains inconclusive to support a benefit of biologic augmentation to core decompression as treatment of osteonecrosis. In 2011 Pak reported a series of case reports evaluating the potential of adipose derived MSCs to regenerate bones in human osteonecrosis. Within this study adipose MSCs were combined with additives such as hyaluronic acid, platelet rich plasma and calcium chloride and injected into the osteonecrotic hip of two subjects and knees of two subjects with OA of the knee. MRI results revealed bone formation and cartilage formation three months post treatment however additional studies are needed to support regeneration was attributed to the MSCs.

Knee Osteoarthritis: The bulk of evidence surrounding stem cell use for orthopaedic conditions has focused on regenerating cartilage for individuals with knee osteoarthritis. Stem cells can be either injected directly into the defect or seeded onto a scaffold providing mechanical support and can be administered with or without adjuvant treatment. Authors contend implantation of subchondral bone marrow MSCs and scaffolds loaded with bone marrow MSCs may improve pain and survivorship of the joint, and potentially reduce the need for surgery (Hernigou, et al., 2021).

Kim et al. (2022) published the results of an RCT assessing intra-articular injection of adipose-derived mesenchymal stem cell (ADMSC) after medial open-wedge high tibial osteotomy (MOWHTO) (n=13) compared to medial open-wedge high tibial osteotomy (MOWHTO) (n=13). Subjects were followed for 24 months. The primary outcome was the serial changes of cartilage defect on periodic magnetic resonance imaging (MRI) evaluation using valid measurements until postoperative 24 months. Secondary outcomes included two stage arthroscopic evaluation for macroscopic articular cartilage status and postoperative functional improvements reported by the patients. At 24 month followup both serial MRIs and arthroscopic evaluation (69.2%, 23.1% respectively) demonstrated that the experimental group had significantly better cartilage regeneration compared with the high-tibial osteotomy group. At 18 months post treatment, functional improvements were also greater in the stem cell group, although not statistically significant. The authors concluded that injection of adipose-derived mesenchymal stem cells is a potential disease modifying treatment for the treatment of knee osteoarthritis without any safety issue. Limitations include small sample population and short term outcomes.

Zhang and colleagues (2022) reported the results of a RCT evaluating the use of stromal vascular fraction injection (n=56) for treatment of knee osteoarthritis compared with hyaluronic acid injection (n=70). Inclusion criteria were meeting the diagnostic criteria in the American Rheumatism Association Revised Classification Criteria for Knee Osteoarthritis; Kellgren–Lawrence (KL) grade 2–3; age 20–85 years; and no history of significant trauma. Subjects were randomly assigned to either the SVF group or a group that received hyaluronic acid (control). Injections

were administered monthly for three months. Subjects were followed for one, two, three, and five years to assess pain and function using VAS and WOMAC scores. Using MRI cartilage structure and volume and bone marrow lesions were assessed over the medial tibia, medial femur, medial patella, lateral tibia, lateral femur, and lateral patella. Clinical failure was defined as surgery related to knee osteoarthritis. A total of 51 subjects in the treatment group and 64 in the control were evaluated at five year followup. The VAS and WOMAC scores in the treatment group were lowest after one year and then increased annually but remained lower than pretreatment scores at five years. The VAS and WOMAC scores in the control group did not change much from pretreatment at 1 year, then increased annually and were significantly higher than pretreatment at 5 years. Kaplan–Meier responsive curves of all patients in the two groups were plotted and compared. The SVF group showed a responsive rate of 62.5% (35/56) at the 5-year follow-up, and the rate in the HA group was 20% (14/70). At the five year followup the total cartilage volume was significantly reduced in both groups from baseline to 5 years, and was higher in the treatment group and small proportion of patients who received stromal vascular fraction had signs of repair of the full-thickness cartilage defect. There was no significant difference in bone marrow lesion size, severity, patella-femoral pathology or mechanical axis from baseline to 5 years and no difference between the two groups. A total of nine subjects underwent surgery during the follow-up period (3 in the SVF group and 6 in the HA group) and were included in the Kaplan-Meier analysis but not the comparison analysis. Limitations of the trial include lack of a targeted injection to a specific lesion site as noted by the authors which precludes knowing the exact destination of the cells, and exclusion of KL Grade 4 subjects which precludes knowing efficacy in this group.

Several authors have published systematic reviews with meta meta-analysis evaluating treatment of knee osteoarthritis using only MSCs (Tan, et al, 2021; Ma, et al., 2020; Prodromos, et al., 2020), MSCs / stromal vascular fractions (Kim, et al., 2021), or MSCs and other biologic agents (Wiggers, et al., 2021; Zhao, et al., 2021; Anil, et al., 2021; Cao, et al., 2021). Within these publications some overlap of studies is noted, however authors tend to report an improvement in pain and function following the intervention (i.e., intra-articular injection of MSCs). Kim and associates (2021) published the results of a systematic review involving five RCTs evaluating the efficacy and safety of intra-articular injections of autologous adipose-derived mesenchymal stem cells (ASCs) or adipose-derived stromal vascular fractions (ADSVFs) without adjuvant treatments, compared with placebo or hyaluronic acid in patients with knee osteoarthritis. VAS scale and WOMAC scores were used to determine pain relief and functional improvement, respectively. Cartilage status was analyzed using MRI. A total of 5 RCTs were included in the review, follow-up occurred at 6 months in one study and 12 months in the remaining four. Based on the meta-analysis, subjects who received ASCs or ADSVFs showed significantly better pain relief at 6 months ($Z = 7.62$; $P \leq .0001$) and 12 months ($Z = 7.21$; $P \leq .0001$) and functional improvement at 6 months ($Z = 4.13$; $P \leq .0001$) and 12 months ($Z = 3.79$; $P = .0002$), without a difference in procedure-related knee pain or swelling compared with controls. A total of three studies reported significantly improved cartilage status after the injection however a meta-analysis was not able to be done due to heterogeneous MRI assessment. Limitations of the review include a small number of studies, small sample sizes, use of variable cell concentrations, and short term follow-up.

Tan et al. (2021) reviewed 19 total studies (Level 1 and 2) evaluating intra-articular injection of MSCs without adjuvant therapy, with a mean duration of followup of 11.9 months, and reported that only the source of MSCs and whether the MSCs were cultured or noncultured were clinically important and statistically significant moderators of the treatment outcome. Bone marrow MSCs reduced VAS for pain by 1.50 and WOMAC by 23.2 compared with adipose MSCs. In addition, the use of cultured MSCs resulted in reduced VAS scores and WOMAC scores compared to non cultured MSCs. Limitations noted by the authors include the level of evidence reviewed (1 and 2) and adequately powered trials, duration of follow-up (range 3-48 months, average 11.9 months) and pooling of studies which could have introduced confounders not controlled for in the original studies.

Anil et al. (2021) evaluated injectable nonoperative treatments for osteoarthritis of the knee using a network meta-analysis of RCTs that included intra-articular injections of various injectates (e.g., autologous conditioned serum, bone marrow aspirate, botulinum toxin, corticosteroids, hyaluronic acid, MSCs, ozone, saline, PRP, plasma rich growth factor, and SVF). A total of 79 RCTs with 8761 subjects were included in the review. VAS scores, and WOMAC scores, when available were analyzed at 1, 3, 6, and 12 months. Clinical outcomes were compared using a frequentist approach and treatments were ranked using the P-score. Follow-up ranged from four weeks to 24 months. At all post-injection time points, the treatment with the highest P-score for VAS score was SVF([P-score Range = 0.8922–99230). Additionally, the authors noted that SVF had the highest

WOMAC score at 12-months post-injection, (P-score = 0.9034), indicating that these patients also had the highest functional outcome scores following treatment. However, worth noting is that according to the authors, the harvest method of SVF in the majority of studies involved the use of collagenase to separate the adipose and in the United States collagenase digestion cannot be used due to FDA regulations. Therefore, for SVF to be used in the United States, it requires mechanical fractioning to separate the SVF from the adipose tissue. Limitations noted by the authors include lack of available data between the studies and reported outcome measures that were obtained at various points during the post-operative period. Additionally, variation in harvest- ing and separating SVF may lead to different therapeutic effects.

Ma et al. (2020) reviewed 10 RCTs and concluded that compared to the control groups intra-articular injected MSCs also resulted in decreased VAS scores and improved WOMAC scores in the short term. Reported follow-up in the studies reviewed was 6-12 months. An increase in cartilage volume occurred in the MSC group compared with the control group, although it was not significant, and although unable to conclude MSCs repair defects, the authors suggest it supports a delay in the degeneration of the cartilage. Limitations of the review include the use of various types of MSCs in the studies, control group heterogeneity, (hyaluronic acid was used in the control group in five of the studies, a placebo in four of the studies, and conservative management in one study), some subjects having advanced OA of Kellgren–Lawrence Grade 4 OA, and lack of complete data in some studies leading to attrition bias.

Prodromos et al. (2020) published the results of a systematic review evaluating autologous mesenchymal stem cell therapy as treatment of knee osteoarthritis. The review included 34 studies entered into three subgroups of studies: Group I included WOMAC and VAS score outcomes (n=29), Group 2 included studies that measured outcomes using other than WOMAC or VAS scores (n=5), and Group 3 included randomized using 1-3 injections of saline as a placebo arm (n=18). Various sources of stem cells were used in the studies including adipose derived stem cells, stromal vascular fraction, bone marrow aspirate, culture expanded bone marrow, and minimally manipulated fat grafts. Follow-up after treatment ranged from six months to 5 years, with a mean of 14.4 months for final followup. All studies in Group I reported significant improvement after treatment at all time points; WOMAC scores and VAS scores improved at six months and final followup, and exceeded the minimal clinically significant difference at all time points. In Group 2 the reported scores improved significantly from baseline to final followup. No dose-response relationship was found between cell dose and outcome. In the author's opinion, stem cell injections for osteoarthritic knee pain results in relief that is longer lasting (at mean of 15.3 months) in comparison to conventional treatments (i.e., corticosteroids, hyaluronan, nonsteroidal anti-inflammatory, and oral analgesics).

Garza and colleagues (2020) evaluated intra-articular stromal vascular fraction (SVF) compared with placebo for reduction of symptoms associated with knee osteoarthritis in a randomized, controlled, double blind trial. Subjects received either high dose SVF (n=13), low dose SVF (n=13) or placebo (no SVF, n=13) injected into the knee joint. Outcomes were measured using WOMAC

scores at 3, 6 and 12 months post injection and MRI at 6 months and one year post treatment. The primary efficacy followup point was six months, as such subjects were unblinded at this point in the trial. The median percent change in WOMAC for high dose, low dose and placebo group was 83.8%, 51.5%, and 25%, respectively at 6 month followup; at one year WOMAC scores were 76.9%, 76.9% and 46.2%, respectively. However, only 26 subjects were available for followup at one year versus 37 at six months. MRI at one year follow-up was available for 23 subjects, there was no evidence of disease progression or change in cartilage thickness. The authors concluded the SVF injections decreased osteoarthritic symptoms for at least 12 months. Limitations of the study include unblinding at 6 months, imputed scores for missing values, small sample size and short term followup. Additional long term evaluation is needed to determine impact to disease progression.

Lee et al. (2019) reported the results of a randomized, double blind placebo controlled trial evaluating high dose autologous adipose derived mesenchymal stem cell (MSC) injection for treatment of knee osteoarthritis. Patient selection criteria included Kellgren-Lawrence grade 2 to 4 osteoarthritis of the knee, pain of at least four or more on the VAS, for at least 12 weeks, and at least one focal or localized grade 3 or 4 lesion on MRI scan. Subjects received either intra-articular injection of normal saline (n=12) or adipose MSC injection (n=12) with followup at one, three and six months post injection. Results demonstrate that at six months followup injection of MSC was associated with improvement in WOMAC score, as compared to baseline (55% reduction), as well as VAS for knee pain, and range of motion. Outcomes for subjects within the control group were not significantly improved. MRI demonstrated no change of cartilage defect at six months in the treatment group, however MRI demonstrated an increased defect in the control group. In the authors opinion there was satisfactory improvement in function and pain relief at six months followup however additional studies are needed with larger sample size to firmly establish clinical efficacy.

A systematic review published by Pas et al. (2017a) evaluated stem cell injections for treatment of knee osteoarthritis. A total of five randomized controlled trials (RCT) and one non RCT met inclusion criteria and were included as part of the review. Inclusion criteria were published and unpublished trials, subjects with any degree of osteoarthritis of the knee, stem cells of any origin compared with any other intervention, a minimal proof of stem cell count/typing, and patient reported outcomes for pain, a validated imaging scoring system and/or adverse events. There was no restriction of time, language or content. In all studies bone-marrow-derived stem cells, adipose-derived mesenchymal stem cells and/or peripheral blood stem cells were used. The number of subjects injected with stem cells ranged from 15 to 36 ; 155 in total were treated with stem cells and 155 served as controls across all studies. In one trial subjects received a total of eight injections, in five trials subjects received only one injection of MSCs. Subjects in five RCTs received injections of platelet rich plasma (PRP) and/or hyaluronic acid (HA) at the same time as MSCs; HA and PRP were also used as monotherapy for the control groups. In two trials uncultured MSCs were used. The authors noted all trials were at high risk of bias, resulting in level-3 evidence. All five RCTs reported superior efficacy for patient-reported outcomes (Visual Analogue Scale, Western Ontario and McMaster Universities Arthritis Index, Tegner, Lysholm, International Knee Documentation Committee, Knee Injury and Osteoarthritis Outcome Score, Lequesne) compared with controls at final follow-up which ranged from 24–48 months. No serious adverse events were reported. Superior radiological outcomes were found favoring stem cell injection. The authors concluded however in the absence of high level evidence stem cell injections for treatment of knee OA is not recommended.

Cui and colleagues (2016) published the results of a meta-analysis evaluating the efficacy of stem cell therapy in treating patients with osteoarthritis. A total of 18 clinical trials met the inclusion criteria, 10 single-arm prospective studies (sample range of 5-41), four quasi-experimental studies (sample range of 18-56), and four RCTs (sample range 50-56). The MSCs utilized were

bone marrow-derived, adipose derived and/or peripheral blood stem cells, some in addition to an activation agent (e.g., collagen matrix, adipose tissue, platelet rich plasma). Follow-up within these trials ranged from three to 24 months. Various outcome measurements included International Knee Documentation Committee (IKDC) scores, Visual Analog Scores (VAS), Tegner and Lysholm scores, and Western Ontario and McMaster Universities OA Index (WOMAC) scores. Compared with pretreatment a pooled effect size was reported as 1.81 at 24 months, with all prior follow-up trending upward, favoring MSC treatment for reducing pain and improving function. A dose related response was unclear regarding the number of MSCs used in treatment. Using only the data from the RCTs MSC treatment was not found to be superior. Transient regional pain and local swelling were the predominant adverse events reported (7 trials) and none of the patients were diagnosed with cancer associated with MSC use. Limitations of the study include small sample size, lack of long term follow-up, varying doses of MSCs, and the addition of activation agents, which also varied among trials.

Vega et al. (2015) reported the results of a RCT evaluating bone marrow-derived MSCs as treatment for osteoarthritis of the knee. All subjects had chronic knee pain and failure of other conservative measures. The control group (n=15) received intra-articular hyaluronic acid while the experimental group (n=15) received intra-articular injections of allogenic bone marrow-derived MSCs. Clinical outcomes were followed for one year and included assessment of pain, disability and quality of life and MRI for assessing cartilage quality. At one year follow-up the treatment group demonstrated decreases in poor cartilage areas, improved quality of cartilage and pain relief. The effects were significant at both 6 and 12 months for MSC treated subjects. The authors noted their results in comparison with other results for autologous bone marrow-derived MSCs was smaller, and for autologous adipose-derived MSCs was similar. The study is limited by short term follow-up and small sample size.

While there is a growing body of evidence, including systematic reviews and meta-analyses, the evidence assessing the safety and effectiveness of MSC therapy remains limited by short term outcomes, lack of controls, use of different sources and quantities of MSCs, inclusion of adjuvant therapy in some trials, and inconsistencies in reporting methods. Although some conclusions support improvement in pain and function for some individuals in the short term, limitations such as heterogeneity of inclusion and exclusion criteria, MSC therapies which have been applied in different stages of osteoarthritis, and lack of long term outcomes prohibit strong evidence based conclusions regarding clinical safety and efficacy.

Muscle/Tendon/Ligament Repair: Stem cell therapy as treatment of tendon and ligament disorders is also an emerging field. Similar to other musculoskeletal tissues tendons and ligaments possess poor regenerative capability. There is a paucity of studies evaluating the efficacy of stem cell therapy for tendon/ligament healing. A systematic review evaluating the evidence for the use of stem cell therapy for tendon disorders was published by Pas, et al., 2017(b). A total of four published trials and three unpublished/pending trials were included in the review (n=79). Two of the trials evaluated bone marrow stem cells injected for treatment of rotator cuff repair, one trial used allogenic adipose derived stem cells for treatment of epicondylar tendinopathy and one trial evaluated bone marrow derived stem cells for treatment patellar tendinopathy. According to the authors all trials were high risk of bias and level four evidence. Absence of controls limited interpretation regarding any benefit. With the exception of the trial using adipose derived stem cells none of the trials using bone marrow MSCs performed cell culturing or cell typing. In epicondylar tendinopathy, patellar tendinopathy and rotator cuff repairs improved healing, functional outcomes and pain scores were reported compared with baseline. Re-rupture of repaired rotator cuffs treated with stem cells preoperatively were reduced in comparison with historical controls or other literature. Only one trial reported adverse events, safety concerns remain. Reporting of cell analysis was inconsistent among trials and it is unknown what if any

effect cell dose had. The authors concluded the evidence was insufficient to support the use of stem cell therapy for treatment of tendon disorders.

Because of their multipotent potential and ability to exert paracrine effects and potential to improve blood flow mesenchymal stem cells have been studied as a treatment of rotator cuff disease (Lin, et al, 2018). Rotator cuff repairs occur most commonly at the tendon-bone interface. During repair, reattaching the tendon to the bone is challenging due to various physiological reasons, often resulting in frequent failure. Nevertheless, there is a paucity of evidence evaluating the effect of MSC therapy for rotator cuff disease and outcomes demonstrating improved healing are inconsistent.

U.S. Food and Drug Administration (FDA)

Medical and surgical procedures do not require FDA approval. In addition, the use of concentrated, autologous mesenchymal stem cells (MSCs) do not require FDA approval. The FDA does regulate human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation, title 21, parts 1270 and 1271. According to the FDA, "the only stem cell-based products that are FDA-approved for use in the United States consist of blood-forming stem cells (hematopoietic progenitor cells) derived from cord blood". Safety concerns of the FDA regarding the use of unproven stem cells include administration site reactions, failure of cells to work as expected, the growth of tumors, and the ability of cells to move from placement sites and change into inappropriate cell types and multiply.

Regenexx®: Regenexx® (Des Moines, Iowa, [previously known as Regenerative Sciences]) "regenerative" procedures (e.g., RegenexxSD® [Same Day Stem Cell Procedure], RegenexxAD® [Adipose Derived Stem Cell Procedure]), have been recommended for treatment of musculoskeletal trauma, overuse injuries, and degenerative issues. During Regenexx® procedures, cells of various derivatives, often from bone, are injected to locally diseased joint areas with the expectation that they will seek out and repair diseased cartilage bone, ligaments and tendons. According to the manufacturer, the Regenexx-Same Day (SD)/Regenexx-SD Plus procedure involves the injection of a highly concentrated stem cell mixture combined with autologous platelet-derived growth factors, referred to as SCP (Super Concentrated Platelets). It has been proposed for a variety of orthopaedic applications including but not limited to repair or regeneration of musculoskeletal tissue, spinal fusion, and bone repair.

In addition, Regenexx describes a licensed culture-expansion site, Regenexx Cayman that provides Regenexx-C (cultured stem cell treatment) and Regenexx Cryopreservation (stem cell storage). The manufacturer asserts these techniques are reported to yield up to 1,000 times more stem cells. Regenexx-C is stated to be ideal for patients with more severe orthopaedic injuries or conditions, patients who want to treat multiple joints, or patients who want to store their stem cells for future treatment. This procedure is not FDA approved.

One randomized controlled (RCT) was located (Centeno, et al., 2018b) in the peer reviewed scientific literature evaluating Regenexx therapy for knee OA. This study included patients with symptomatic knee osteoarthritis (n=48) who were assigned to either an exercise therapy control group (n=22) or treatment group with image-guided injection of autologous bone marrow concentrate (BMC) and platelet products (n=26). At three months subjects were allowed to crossover to the bone marrow treatment group. Measured outcomes included the Knee Society Score (KSS), Pain Visual Analogue Scale, Short Form-12 Scales (SF-12), and Lower Extremity Activity Scale (LEAS). Follow-up for clinical outcomes occurred at 6-weeks, 3, 6, 12 and 24 months. A total of 14 patients were lost to follow-up. All 22 patients in the control group crossed over to BMC treatment after three months. Patients who received a specific protocol of BMC and platelet products improved significantly in activity levels, as well as pain, range of motion and stability, compared to patients who underwent a home exercise therapy program for 3 months.

Pain decreased for both the exercise therapy and the BMC groups, and function increased for the BMC group, although did not differ significantly between the 2 groups. Exercise therapy provided significant improvements in ROM and activity levels at 3-months compared to baseline. No serious adverse events were reported. Limitations of this RCT include the small sample size and the allowance of those in the exercise group to crossover at three months and receive BMC. Additional controlled studies with larger sample sizes evaluating Regenexx processes/procedures/products are needed to support safety and effectiveness.

In 2020 Centeno et al. published mid-term results of a randomized controlled trial evaluating the use of bone marrow concentrate and platelet rich plasma versus exercise therapy as treatment for rotator cuff tears (n=25, 14 subjects in the bone marrow group, 11 subjects in the exercise therapy group). The study is ongoing and the authors note enrolment continues however the midterm review includes the reported outcomes of subjects who reached 12 month followup (n=24). The preliminary outcomes suggest a size decrease in most tears post bone marrow treatment, and improvements in DASH and NPS scores at three and six months compared to exercise. However, final outcomes are pending completion of the study.

The overall body of evidence indicates that safety and efficacy of Regenexx procedures, including BMC with platelet rich plasma and other lysate preparations, are currently unproven. Although the body of evidence is emerging, concerns regarding quality and oversight, preparation, application/procedure, safety, clinical utility, and durability have been reported among authors.

Cartistem®: Cartistem® is a combination of human umbilical cord blood-derived mesenchymal stem cells and sodium hyaluronate, and is intended to be used as a single-dose therapeutic agent for cartilage regeneration in humans with cartilage defects of the knee as a result of aging, trauma, or degenerative diseases. Although published results are not found in peer-reviewed at this time according to ClinicalTrials.gov studies are underway evaluating the efficacy and safety of Cartistem®.

Lipogem®: Lipogem® Microfragmented Adipose Tissue Transplant System (Lipogem, Norcross, GA) is an adipose-derived regenerative cell therapy described by the manufacturer as closed circuit processing system used to remove adipose tissue from the body and transfer it via injection into a patient's injured joint or diseased soft tissue. It is asserted Lipogem preserves the structural properties and microarchitecture of the original tissue: the scaffold (the adipose tissue and the stromal structure), the cells (endothelium, pericytes / MSCs), and the growth factors (cytokines and chemokines). Lipogem received FDA 510(k) approval in 2016 as a suction lipoplasty system. It is noted with the 510(k) approval the device is intended for use in the following surgical specialties when the transfer of harvested adipose tissue is desired: orthopaedic surgery, arthroscopic surgery, neurosurgery, gastrointestinal and affiliated organ surgery, urological surgery, general surgery, gynecological surgery, thoracic surgery, laparoscopic surgery, and plastic and reconstructive surgery when aesthetic body contouring is desired (FDA, K161636). Panchal et al (2018) reported on 17 subjects with osteoarthritis of the knee who underwent Lipogem injection intra-articularly under ultrasound guidance. Pre and post treatment outcomes were collected at six weeks, six months and 12 months following therapy using NPRS (numerical pain rating scale), the 100-point Knee Society Score (KSS) and lower extremity activity scale (LEAS). Although the authors reported significant improvements in NPRS, mean KSS at 12 months the study is limited by small sample population, lack of control, and short term outcomes. Additional research is required to support clinical efficacy.

Professional Societies/Organizations

American Academy of Orthopaedic Surgeons (AAOS): The AAOS published an evidence based clinical practice guideline, endorsed by several other societies, on the management of glenohumeral joint OA (AAOS, 2020). Within this guideline the AAOS states that injectable

biologics, such as stem cells, are not recommended in the treatment of glenohumeral joint osteoarthritis. There is consensus from the panel that better standardization and high-quality evidence from clinical trials is needed to provide definitive evidence on the efficacy of biologics in glenohumeral osteoarthritis. The strength of evidence was graded as “No reliable evidence” to determine benefits and harms. The AAOS guidelines on the management of osteoarthritis of the knee and hip do not address stem cell injection (AAOS, 2021; AAOS, 2023).

The American College of Rheumatology (ACR) and Arthritis Foundation: The ACR and Arthritis Foundation published guidelines on osteoarthritis of the hand, hip, and knee and provide a strong recommendation against stem cell injections in patients with knee and/or hip osteoarthritis noting the “heterogeneity in preparations and lack of standardization of techniques”. A recommendation was not made for hand osteoarthritis within the guideline because the use of stem cells has not been evaluated for this condition (Kolasinski, et al., 2020).

Department of veterans Affairs and the Department of Defense (VA/DoD): In a 2020 clinical practice guideline for the non-surgical management of hip and knee osteoarthritis, the VA/DoD gave a “weak against” recommendation for the use of stem cell injections for the treatment of osteoarthritis of the knee. The guideline is based on two systematic reviews and eight randomized controlled trials that were limited by inconsistency and imprecision with study designs and outcome measures, lack of studies evaluating the therapy in individuals with hip osteoarthritis, and incomplete reporting (VA/DoD, 2020).

Medicare Coverage Determinations

	Contractor	Determination Name/Number	Revision Effective Date
NCD	National	No NCD found	
LCD	Local	No LCD found	

Note: Please review the current Medicare Policy for the most up-to-date information.
(NCD = National Coverage Determination; LCD = Local Coverage Determination)

Coding Information

Notes:

1. This list of codes may not be all-inclusive since the American Medical Association (AMA) and Centers for Medicare and Medicaid Services (CMS) code updates may occur more frequently than policy updates.
2. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

Considered Not Medically Necessary:

CPT®* Codes	Description
20999	Unlisted procedure, musculoskeletal system, general
38230	Bone marrow harvesting for transplantation; allogeneic
38232	Bone marrow harvesting for transplantation; autologous
0565T	Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; tissue harvesting and cellular implant creation
0566T	Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; injection of cellular implant into knee joint including ultrasound guidance, unilateral

CPT®* Codes	Description
0717T	Autologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tear; adipose tissue harvesting, isolation and preparation of harvested cells, including incubation with cell dissociation enzymes, filtration, washing and concentration of ADRCs
0718T	Autologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tear; injection into supraspinatus tendon including ultrasound guidance, unilateral

Considered Not Medically Necessary when used to report stem cells used as treatment of orthopaedic and/or musculoskeletal conditions:

HCPCS Codes	Description
P9099	Blood component or product not otherwise classified

***Current Procedural Terminology (CPT®) ©2023 American Medical Association: Chicago, IL.**

References

1. Ahmad Z, Wardale J, Brooks R, Henson F, Noorani A, Rushton N. Exploring the application of stem cells in tendon repair and regeneration. *Arthroscopy*. 2012 Jul;28(7):1018-29.
2. American Academy of Orthopaedic Surgeons. Evidence-based Clinical Practice Guidelines. Management of Osteoarthritis of the Knee (Non Arthroplasty). Published August 2021. Accessed Oct 10, 2024. Available at URL address: <https://www.aaos.org/quality/quality-programs/osteoarthritis-of-the-knee/>
3. American Academy of Orthopaedic Surgeons. Evidence-based Clinical Practice Guidelines. Management of Glenohumeral Joint Osteoarthritis. Published March 2020. Accessed Oct 10, 2024. Available at URL address: <https://www.aaos.org/quality/quality-programs/glenohumeral-joint-osteoarthritis/>
4. American Academy of Orthopaedic Surgeons. Evidence-based Clinical Practice Guidelines. Management of Osteoarthritis of the Hip (Non Arthroplasty). Published Dec 2023. Accessed Oct 10, 2024. Available at URL address: <https://www.aaos.org/quality/quality-programs/osteoarthritis-of-the-hip/>
5. Burke J, Hunter M, Kolhe R, Isales C, Hamrick M, Fulzele S. Therapeutic potential of mesenchymal stem cell based therapy for osteoarthritis. *Clin Transl Med*. 2016 Dec;5(1):27.
6. Centeno C, Fausel Z, Stemper I, Azuik U, Dodson E. A Randomized Controlled Trial of the Treatment of Rotator Cuff Tears with Bone Marrow Concentrate and Platelet Products Compared to Exercise Therapy: A Midterm Analysis. *Stem Cells Int*. 2020 Jan 30;2020:5962354.
7. Centeno C, Markle J, Dodson E, et al. Symptomatic anterior cruciate ligament tears treated with percutaneous injection of autologous bone marrow concentrate and platelet products: a non-controlled registry study. *J Transl Med*. 2018a Sep 3;16(1):246.

8. Centeno CJ, Pitts J, Al-Sayegh H, Freeman MD. Anterior cruciate ligament tears treated with percutaneous injection of autologous bone marrow nucleated cells: a case series. *J Pain Res.* 2015 Jul 31;8:437-47.
9. Centeno CJ, Pitts JA, Al-Sayegh H, Freeman MD. Efficacy and Safety of Bone Marrow Concentrate for Osteoarthritis of the Hip; Treatment Registry Results for 196 Patients. *J Stem Cell Res Ther* 2014, 4-10.
10. Centeno C, Sheinkop M, Dodson D, et al. A specific protocol of autologous bone marrow concentrate and platelet products versus exercise therapy for symptomatic knee osteoarthritis: a randomized controlled trial with 2 year follow-up. *J Trans Med.* 2018b; 16:355.
11. Centeno C, Schultz JR, Cheever M, et al. A Case Series of Percutaneous Treatment of Non-Union Fractures with Autologous, Culture Expanded, Bone Marrow Derived, Mesenchymal Stem Cells and Platelet Lysate. *Journal of Bioengineering & Biomedical Science.* 2011, S2.
12. Chew E, Prakash R, Khan W. Mesenchymal stem cells in human meniscal regeneration: A systematic review. *Ann Med Surg (Lond).* 2017 Oct 5;24:3-7.
13. Cook J, Young M. Biologic therapies for tendon and muscle injury. UpToDate®. July 10, 2019, Updated August 2022.
14. Cui GH, Wang YY, Li CJ, Shi CH, Wang WS. Efficacy of mesenchymal stem cells in treating patients with osteoarthritis of the knee: A meta-analysis. *Exp Ther Med.* 2016 Nov;12(5):3390-3400.
15. Delanois RE, Etcheson JI, Sodhi N, Henn RF 3rd, Gwam CU, George NE, Mont MA. Biologic Therapies for the Treatment of Knee Osteoarthritis. *J Arthroplasty.* 2019 Apr;34(4):801-813.
16. Emadedin M, Labibzadeh N, Liastani MG, et al. Intra-articular implantation of autologous bone marrow-derived mesenchymal stromal cells to treat knee osteoarthritis: a randomized, triple-blind, placebo-controlled phase 1/2 clinical trial. *Cytotherapy.* 2018 Oct;20(10):1238-1246.
17. Filardo G, Madry H, Jelic M, et al. Mesenchymal Stem Cells for the Treatment of Cartilage Lesions: From Preclinical Findings to Clinical Application in Orthopaedics. *Knee Surg Sports Traumatol Arthrosc* 2013 aug;21(8):1717-29.
18. Garza JR, Campbell RE, Tjoumakaris FP, Freedman KB, Miller LS, Santa Maria D, Tucker BS. Clinical Efficacy of Intra-articular Mesenchymal Stromal Cells for the Treatment of Knee Osteoarthritis: A Double-Blinded Prospective Randomized Controlled Clinical Trial. *Am J Sports Med.* 2020 Mar;48(3):588-598.
19. Gepstein L, Skorecki K. Regenerative Medicine, Cell and Gene Therapies. *Goldman-Cecil Medicine* 38, 183-195. 26th edition. Copyright © 2020 by Elsevier.
20. Goldberg A, Mitchell K, Soans J, et al. The use of mesenchymal stem cells for cartilage repair and regeneration: a systematic review. *J Ortho Surg Res.* Mar 09 2017;12(1):39.

21. Ha CW, Park YB, Kim SH, Lee HJ. Intra-articular Mesenchymal Stem Cells in Osteoarthritis of the Knee: A Systematic Review of Clinical Outcomes and Evidence of Cartilage Repair. *Arthroscopy*. 2019 Jan;35(1):277-288.e2.
22. Hernigou P, Bouthors C, Bastard C, Flouzat Lachaniette CH, Rouard H, Dubory A. Subchondral bone or intra-articular injection of bone marrow concentrate mesenchymal stem cells in bilateral knee osteoarthritis: what better postpone knee arthroplasty at fifteen years? A randomized study. *Int Orthop*. 2021 Feb;45(2):391-399.
23. Hernigou J, Vertongen P, Rasschaert J, Hernigou P. Role of Scaffolds, Subchondral, Intra-Articular Injections of Fresh Autologous Bone Marrow Concentrate Regenerative Cells in Treating Human Knee Cartilage Lesions: Different Approaches and Different Results. *Int J Mol Sci*. 2021 Apr 8;22(8):3844.
24. Jevotovsky DS, Alfonso AR, Einhorn TA, Chiu ES. Osteoarthritis and stem cell therapy in humans: a systematic review. *Osteoarthritis Cartilage*. 2018 Jun;26(6):711-729.
25. Khan S, Mafi P, Mafi R, Khan W. A Systematic Review of Mesenchymal Stem Cells in Spinal Cord Injury, Intervertebral Disc Repair and Spinal Fusion. *Curr Stem Cell Res Ther*. 2018;13(4):316-323.
26. Kim KI, Kim MS, Kim JH. Intra-articular Injection of Autologous Adipose-Derived Stem Cells or Stromal Vascular Fractions: Are They Effective for Patients With Knee Osteoarthritis? A Systematic Review With Meta-analysis of Randomized Controlled Trials. *Am J Sports Med*. 2022 Jan 12:3635465211053893.
27. Kim JH, Kim KI, Yoon WK, Song SJ, Jin W. Intra-articular Injection of Mesenchymal Stem Cells After High Tibial Osteotomy in Osteoarthritic Knee: Two-Year Follow-up of Randomized Control Trial. *Stem Cells Transl Med*. 2022 Jun 22;11(6):572-585.
28. Koh YG, Jo SB, Kwon OR, Suh DS, Lee SW, Park SH, Choi YJ. Mesenchymal stem cell injections improve symptoms of knee osteoarthritis. *Arthroscopy*. 2013 Apr;29(4):748-55.
29. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. *Arthritis Care Res (Hoboken)*. Feb 2020; 72(2): 149-162.
30. Lee WS, Kim HJ, Kim KI, Kim GB, Jin W. Intra-Articular Injection of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis: A Phase IIb, Randomized, Placebo-Controlled Clinical Trial. *Stem Cells Transl Med*. 2019 Jun;8(6):504-511.
31. Lee WY, Wang B. Cartilage repair by mesenchymal stem cells: Clinical trial update and perspectives. *J Orthop Translat*. 2017 Apr 9;9:76-88.
32. Li J, Su P, Li J, Chen G, Xiong Y. Efficacy and Safety of Stem Cell Combination Therapy for Osteonecrosis of the Femoral Head: A Systematic Review and Meta-Analysis. *J Healthc Eng*. 2021 Sep 24;2021:9313201.
33. Lin KM, Wang D, Dines JS. Injection therapies for rotator cuff disease. *Orthop Clin N Am* 49 (2018) 231-239.

34. Ma W, Liu C, Wang S, et al. Efficacy and safety of intra-articular injection of mesenchymal stem cells in the treatment of knee osteoarthritis. A systematic review and meta analysis. *Medicine (Baltimore)*. 2020 Dec 4;99(49):e23343.
35. Matsukura Y, Muneta T, Tsuji K, Koga H, Sekiya I. Mesenchymal stem cells in synovial fluid increase after meniscus injury. *Clin Orthop Relat Res*. 2014 May;472(5):1357-64.
36. Migliorini F, Rath B, Colarossi G, et al. Improved outcomes after mesenchymal stem cells injections for knee osteoarthritis: results at 12-months follow-up: a systematic review of the literature. *Arch Orthop Trauma Surg*. 2019 Aug 27.
37. Mobasheri A, Kalamegam G, Musameci M, Batt M. Chondrocyte and mesenchymal stem cell-based therapies for cartilage repair in osteoarthritis and related orthopaedic conditions. *Maturitas*. 78 (2014) 188–198.
38. Natali S, Screpis D, Farinelli L, Iacono V, Vacca V, Gigante A, Zorzi C. The use of intra-articular injection of autologous micro-fragmented adipose tissue as pain treatment for ankle osteoarthritis: a prospective not randomized clinical study. *Int Orthop*. 2021 Sep;45(9):2239-2244.
39. National Institute of Health (NIH). Turning discovery into health: regenerative medicine innovation project. Page last reviewed Dec 14, 2022. Accessed Oct 11, 2024. Available at URL address: <https://www.nih.gov/rmi>
40. National Institute of Health (NIH). National Library of Medicine. ClinicalTrials.gov. Accessed Oct 11, 2024. Available at URL address: <https://clinicaltrials.gov/>
41. Pak J. Regeneration of human bones in hip osteonecrosis and human cartilage in knee osteoarthritis with autologous adipose-tissue-derived stem cells: a case series. *J Med Case Rep*. 2011 Jul 7;5:296.
42. Panchal J, Malanga G, Sheinkop M. Safety and Efficacy of Percutaneous Injection of Lipogems Micro-Fractured Adipose Tissue for Osteoarthritic Knees. *Am J Orthop (Belle Mead NJ)*. 2018 Nov;47(11).
43. Park YB, Ha CW, Rhim JH, Lee HJ. Stem Cell Therapy for Articular Cartilage Repair: Review of the Entity of Cell Populations Used and the Result of the Clinical Application of Each Entity. *Am J Sports Med*. 2018 Aug;46(10):2540-2552.
44. Pas HI, Winters M, Haisma HJ, Koenis MJ, Tol JL, Moen MH. Stem cell injections in knee osteoarthritis: a systematic review of the literature. *Br J Sports Med*. 2017a Aug;51(15):1125-1133.
45. Pas HIMFL, Moen MH, Haisma HJ, Winters M. No evidence for the use of stem cell therapy for tendon disorders: a systematic review. *Br J Sports Med*. 2017b Jul;51(13):996-1002.
46. Prodromos C, Finkle S, Rumschlag T, Lotus J. Autologous Mesenchymal Stem Cell Treatment is Consistently Effective for the Treatment of Knee Osteoarthritis: The Results of a Systematic Review of Treatment and Comparison to a Placebo Group. *Medicines (Basel)*. 2020 Jul 24;7(8):42.

47. Rinonapoli G, Gregori P, Di Matteo B, Impieri L, Ceccarini P, Manfreda F, Campofreda G, Caraffa A. Stem cells application in meniscal tears: a systematic review of pre-clinical and clinical evidence. *Eur Rev Med Pharmacol Sci*. 2021 Dec;25(24):7754-7764.
48. Simunec D, Salari H, Meyer J. Treatment of Grade 3 and 4 Osteoarthritis with Intraoperatively Separated Adipose Tissue-Derived Stromal Vascular Fraction: A Comparative Case Series. *Cells*. 2020 Sep 14;9(9):2096.
49. Tan SHS, Kwan YT, Neo WJ, Chong JY, Kuek TYJ, See JZF, Wong KL, Toh WS, Hui JHP. Intra-articular Injections of Mesenchymal Stem Cells Without Adjuvant Therapies for Knee Osteoarthritis: A Systematic Review and Meta-analysis. *Am J Sports Med*. 2021 Sep;49(11):3113-3124.
50. U. S. Food and Drug Administration (FDA). 510(k) Premarket Notification Database. Product codes: PLP. Page last updated: Oct 7, 2024. Accessed Oct 11, 2024. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm>
51. VA/DoD Clinical practice guideline for the non-surgical management of hip and knee osteoarthritis. Washington, D.C.: Dept. of Veterans Affairs, Dept. of Defense, 2020. Accessed Oct 11, 2024. Available at URL address: <https://www.healthquality.va.gov/guidelines/CD/OA/index.asp>
52. Vangsness CT Jr, Farr J 2nd, Boyd J, Dellaero DT, Mills CR, LeRoux-Williams M. Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy: a randomized, double-blind, controlled study. *J Bone Joint Surg Am*. 2014 Jan 15;96(2):90-8.
53. Vannabouathong C, Del Fabbro G, Sales B, Intra-articular Injections in the Treatment of Symptoms from Ankle Arthritis: A Systematic Review. *Foot Ankle Int*. 2018 Oct;39(10):1141-1150.
54. Vega A, Martín-Ferrero MA, Del Canto F, et al., Treatment of Knee Osteoarthritis With Allogeneic Bone Marrow Mesenchymal Stem Cells: A Randomized Controlled Trial. *Transplantation*. 2015 Aug;99(8):1681-90.
55. Wang M, Yuan Q, Xie L. Mesenchymal Stem Cell-Based Immunomodulation: Properties and Clinical Application. *Stem Cells Int*. 2018 Jun 14;2018:3057624.
56. Wang Y, Han ZB, Song YP, Han ZC. Safety of mesenchymal stem cells for clinical application. *Stem Cells Int*. 2012;2012:652034.
57. Wiggers TG, Winters M, Van den Boom NA, Haisma HJ, Moen MH. Autologous stem cell therapy in knee osteoarthritis: a systematic review of randomised controlled trials. *Br J Sports Med*. 2021 Oct;55(20):1161-1169.
58. Yi H, Wang Y, Liang Q, Mao X. Preclinical and Clinical Amelioration of Bone Fractures with Mesenchymal Stromal Cells: a Systematic Review and Meta-Analysis. *Cell Transplant*. 2022 Jan-Dec;31:9636897211051743.
59. Zhang S, Xu H, He B, Fan M, Xiao M, Zhang J, Chen D, Tong P, Mao Q. Mid-term prognosis of the stromal vascular fraction for knee osteoarthritis: a minimum 5-year follow-up study. *Stem Cell Res Ther*. 2022 Mar 12;13(1):105.

60. Zhao D, Pan JK, Yang WY, Han YH, Zeng LF, Liang GH, Liu J. Intra-Articular Injections of Platelet-Rich Plasma, Adipose Mesenchymal Stem Cells, and Bone Marrow Mesenchymal Stem Cells Associated With Better Outcomes Than Hyaluronic Acid and Saline in Knee Osteoarthritis: A Systematic Review and Network Meta-analysis. *Arthroscopy*. 2021 Jul;37(7):2298-2314.e10.

Revision Details

Type of Revision	Summary of Changes	Date
Annual Review	Revised policy statement for stem cell therapy.	12/15/2024
Focused Review	Removed policy statement for degenerative disc disease.	11/1/2024
Annual Review	No clinical policy statement changes.	3/15/2024

“Cigna Companies” refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2024 The Cigna Group.